Operator
Good morning, and welcome to the MannKind Corporation conference call to discuss the U.S. FDA approval of Furoscix ReadyFlow. As a reminder, this call is being recorded on July 24, 2026, and will be made available for replay on the MannKind Corporation website shortly after this call for approximately 90 days.
This call will contain forward-looking statements. Such forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from these expectations. For further information on the company’s risk factors, please see the Form 10-Q for the period ending March 31, 2026, this morning’s press release and the slides prepared for this presentation.
Joining us today from MannKind are Chief Executive Officer, Michael Castagna; and Chief Medical Officer, Dr. Ajay Ahuja.
I would now like to turn the conference call over to Mr. Castagna, please. Go ahead, sir.
Michael Castagna
CEO & Director
Thanks, operator, and good morning, everyone. Thank you for joining us on what is an exciting day for MannKind. Here’s our agenda for this morning. I’ll start with the approval and what it means. Then I’ll turn it over to Dr. Ajay Ahuja, our Chief Medical Officer, to walk through our clinical overview of
